Irbesartan/Hydrochlorothiazide Zydus

Irbesartan/Hydrochlorothiazide, the active ingredients in Irbesartan/Hydrochlorothiazide Zydus, are an Angiotensin II receptor blocker / Thiazide diuretic presented as a fixed‑dose oral tablet for oral use. They are indicated for the management of elevated blood pressure in adult patients. The combination leverages complementary mechanisms of an ARB and a thiazide diuretic to achieve improved blood pressure control.

GNH USA supplies Irbesartan/Hydrochlorothiazide Zydus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution in diverse markets.

Irbesartan/Hydrochlorothiazide is used to treat hypertension, providing blood‑pressure reduction through combined ARB and diuretic action. - Hypertension (essential): lowers systolic and diastolic pressure in patients with primary hypertension. - Hypertension with fluid retention: controls blood pressure while promoting diuresis to reduce excess fluid. - Hypertension requiring combination therapy: offers dual mechanism in a single tablet for patients needing both an ARB and a thiazide diuretic.

The most frequently reported adverse reactions with Irbesartan/Hydrochlorothiazide are listed below.

Common Side Effects: - Dizziness - Headache - Fatigue - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration - Acute kidney injury - Hyperkalemia - Allergic reactions (rash, angioedema) - Gout attacks - Severe hypotension

When prescribing Irbesartan/Hydrochlorothiazide, clinicians should consider the following precautions. - Renal function: assess baseline kidney function and monitor creatinine. - Electrolytes: check serum potassium and sodium before initiation and during therapy. - Volume status: avoid use in patients with severe dehydration or volume depletion. - Concomitant drugs: use caution with other potassium‑sparing agents or NSAIDs. - Pregnancy: avoid use during pregnancy due to unknown fetal risk. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and light.

Irbesartan/Hydrochlorothiazide may interact with several medicines; notable interactions are categorized below.

Major Interactions (Avoid): - Aliskiren: combined use can increase risk of renal impairment and hyperkalemia. - Lithium: thiazide component may raise lithium levels, risking toxicity. - Potassium supplements or potassium‑sparing diuretics: may cause dangerous hyperkalemia.

Moderate Interactions (Monitor Closely): - ACE inhibitors or other ARBs: additive blood‑pressure effects may cause hypotension. - NSAIDs: can reduce antihypertensive efficacy and affect renal function. - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan plasma concentrations.